Third-line treatment options in metastatic pancreatic cancer patients: a real-world study.

ABSTRACT:

Background

There are currently no standard therapy regimens for the third-line treatment of metastatic pancreatic cancer (mPC) patients. The aim of the present study was to compare the efficacy and safety of different third-line therapy regimens for mPC in the real-world.

Methods

This study retrospectively analyzed mPC patients admitted to Zhejiang Provincial People's Hospital between June 2013 and January 2023. All patients' diagnoses were pathologically confirmed and their treatment was continued after the second-line therapy failed. The primary study endpoints included median overall survival (mOS), median progression-free survival (mPFS), and disease control rate (DCR).

Results

A total of 72 patients were enrolled in the study. Of these, 36 patients received chemo

SUBMITTER: Lu HR 

PROVIDER: S-EPMC10552515 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature